Osnat Benshoshan Joins Luventix Advisory Board
Luventix, a pioneer in Intelligent Disease Diagnostics, is excited to announce the appointment of Osnat Benshoshan to its Advisory Board.
Ms. Benshoshan, a seasoned executive with extensive experience in global business development, marketing, and strategic leadership, has a proven track record of driving growth and innovation in the technology and life sciences sectors. With her expertise in building high-impact partnerships and delivering market-expanding strategies, she will provide valuable guidance as Luventix continues its trajectory of innovation and growth.
"We are delighted to welcome Osnat Benshoshan to our Advisory Board," said George Holmes, CEO of Luventix. "Her deep understanding of global markets and her ability to foster impactful collaborations align seamlessly with our mission to drive down the cost of healthcare by making low cost diagnostics solutions available to all!."
Ms. Benshoshan’s appointment reinforces Luventix’s commitment to integrating world-class expertise as it continues to deliver cutting-edge solutions in urine based diagnostics.
About Luventix
Luventix is a medical diagnostics company utilizing a simple, non-invasive urine test to detect and diagnose diseases through metabolomics modeling. By leveraging proprietary advanced machine learning (ML) modeling techniques, Luventix has the unique ability to analyze data and pinpoint disease-specific signatures within a Digital Twin, bridging the gap between diagnostics and therapeutics, revolutionizing clinical trial recruitment and enabling companion diagnostics as an integral endpoint.
With a commitment to innovation, collaboration, and excellence, Luventix is redefining industry standards and making a meaningful impact on healthcare outcomes. By combining cutting-edge technology with strategic partnerships, Luventix aims to transform the landscape of personalized medicine and accelerate the delivery of life-changing solutions. For more information, please visit www.luventix.com
Media Contact:
